Levaggi, Rosella, 1962-....
Levaggi, Rosella
Rosella Levaggi researcher
VIAF ID: 112199045 (Personal)
Permalink: http://viaf.org/viaf/112199045
Preferred Forms
- 200 _ | ‡a Levaggi ‡b Rosella ‡f 1962-....
- 100 1 _ ‡a Levaggi, Rosella
-
-
- 100 1 _ ‡a Levaggi, Rosella ‡d 1962-...
- 100 1 0 ‡a Levaggi, Rosella, ‡d 1962-
-
- 100 1 _ ‡a Levaggi, Rosella, ‡d 1962-....
- 100 0 _ ‡a Rosella Levaggi ‡c researcher
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
Cost-effectiveness of pre-participation screening of athletes with ECG in Europe and Algeria | |
Cross border health care provision: who gains, who loses. | |
Definition of a prospective payment system to reimburse emergency departments | |
Developments in local government finance | |
Devolution and grant-in-aid design for the provision of impure public goods | |
Emotions in physician agency | |
Fiscal federalism and grants-in-aid : the problem of asymmetrical information | |
Health care expenditure decisions in the presence of devolution and equalisation grants. | |
Health care provision and patient mobility health integration in the European Union | |
Hospital health care: pricing and quality control in a spatial model with asymmetry of information | |
Innovation, aging, and health care: Unraveling "silver" from "red" herrings? | |
Laboratory considerations amidst the coronavirus disease 2019 outbreak: the Spedali Civili in Brescia experience | |
Monitoring air pollution effects on children for supporting public health policy: the protocol of the prospective cohort MAPEC study | |
Not a good buy: value for money of prescription drugs sold on the internet | |
Patient mobility and health care quality when regions and patients differ in income | |
Patient mobility in the context of austerity and an enlarged EU: The European Court of Justice's ruling in the Petru Case | |
Pricing schemes for new drugs: a welfare analysis. | |
The redistributive effects of copayment in outpatient prescriptions: evidence from Lombardy | |
Should I pay for your risky behaviours? Evidence from London. | |
Soft budget constraints in health care: evidence from Italy. | |
Standardised pre-competitive screening of athletes in some European and African countries: the SMILE study. | |
Static and dynamic efficiency of irreversible health care investments under alternative payment rules | |
Two-part payments for the reimbursement of investments in health technologies | |
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition | |
Which valued-based price when patients are heterogeneous? |